9/11 Basal Cell Carcinoma Claims: VCF Compensation & WTC Health Program Benefits

Who qualifies for 9/11 basal cell carcinoma compensation?

Anyone diagnosed with basal cell carcinoma following presence in the New York City exposure zone, at the Pentagon, or in Shanksville, Pennsylvania during the covered period may qualify for VCF compensation. This includes area workers, residents, students, teachers, first responders, cleanup and recovery workers, volunteers, and surviving family members of those who died from a 9/11-related basal cell carcinoma.

Basal cell carcinoma is the most common cancer of any type in the United States, per American Cancer Society reference data, and appears with high frequency in the 9/11 community. The dust and debris that settled on skin in the weeks and months after September 11, combined with the sun exposure history typical of the general adult population, produce a large certified BCC caseload each year.

What types of basal cell carcinoma are covered by the WTC Health Program?

The WTC Health Program certifies malignant basal cell carcinoma of the skin. Coverage includes the common histologic subtypes, distinguished primarily by growth pattern under the microscope and by their behavior on the skin:

• Nodular basal cell carcinoma — the most common subtype, per American Cancer Society reference data. Presents as a pearly, waxy bump, often with visible surface blood vessels, most commonly on the face, ears, and neck.
• Superficial basal cell carcinoma — presents as a flat, scaly, reddish or pinkish patch, most often on the trunk or shoulders. Frequently misdiagnosed as eczema or psoriasis before biopsy.
• Morpheaform (sclerosing or infiltrative) basal cell carcinoma — a more aggressive growth pattern that infiltrates surrounding tissue with poorly defined borders. Higher risk of recurrence and of extensive tissue involvement at excision.
• Pigmented basal cell carcinoma — contains melanin pigment and can visually resemble melanoma. Distinguished on biopsy.
• Basosquamous carcinoma — a mixed pattern with features of both basal cell carcinoma and squamous cell carcinoma. Behaves more aggressively than typical BCC and carries a higher metastatic risk than standard nodular BCC.

Under 42 C.F.R. §88.15, the WTCHP certifies basal cell carcinoma regardless of subtype or anatomic site. The subtype and location affect the medical treatment path and can affect economic loss compensation but do not affect certifiability.

More than 400,000 people are estimated to have been exposed to 9/11 toxins in the New York Exposure Zone alone, with additional exposures at the Pentagon and Shanksville, Pennsylvania. The dust, smoke, and debris released by the collapse of the World Trade Center contained known and suspected carcinogens including asbestos, silica, polycyclic aromatic hydrocarbons, dioxins, furans, heavy metals, and other combustion byproducts.

Skin was one of the most directly exposed organs — dust settled on the face, neck, forearms, and any uncovered surface, and prolonged contact was the norm for responders, cleanup workers, and residents returning to Lower Manhattan.

Basal cell carcinoma arises through cumulative DNA damage in the basal cells at the bottom of the epidermis. Ultraviolet radiation is the most well-established cause, but chemical carcinogens — including several documented in the 9/11 dust — also contribute. Polycyclic aromatic hydrocarbons and arsenic, both present in the WTC debris field, have long been recognized as chemical carcinogens with a documented association with non-melanoma skin cancer, including basal cell carcinoma.

Basal cell carcinoma does not appear immediately after exposure. There is typically a period of years between exposure and clinical detection. The WTC Health Program requires a minimum four-year latency period between first 9/11 exposure and first basal cell carcinoma diagnosis before certification.

Certification does not require proof that 9/11 exposure was the only cause of a particular basal cell carcinoma. Under federal law, the standard is whether the exposure was substantially likely to be a significant factor in aggravating, contributing to, or causing the condition. Fair skin, cumulative sun exposure, prior tanning bed use, family history, and other established BCC risk factors are common in the 9/11 community and generally do not prevent certification.

Basal cell carcinoma typically presents as a slow-growing lesion on sun-exposed skin — most commonly on the face, ears, neck, scalp, shoulders, or upper back. It rarely causes pain in early stages, which is why many people leave it unaddressed until it grows, bleeds, or fails to heal. Any lesion matching the descriptions below in a person with 9/11 exposure history should be evaluated by a WTC Health Program participating dermatologist.

• A pearly, waxy, or translucent bump with visible surface blood vessels, most common on the head and neck
• A flat, scaly, reddish or pinkish patch on the trunk or shoulders that does not resolve
• A shiny, flesh-colored or pale scar-like area with poorly defined borders
• A sore that heals and then returns, or bleeds without an obvious cause
• A raised, rolled border around a central depression or ulceration
• A pigmented lesion that resembles a mole but has the surface characteristics of BCC

Untreated basal cell carcinoma can grow deep into surrounding tissue. On the face, extensive BCC can invade cartilage, bone, and — in rare cases involving perineural spread — nearby nerves. This local tissue destruction, rather than metastasis, is the primary morbidity concern with basal cell carcinoma. Early detection through routine dermatology examination is the most reliable way to prevent extensive surgery.

The WTC Health Program requires a minimum four-year latency period between first 9/11 exposure and first basal cell carcinoma diagnosis. This latency requirement is set out in federal regulation and has no exceptions. A basal cell carcinoma diagnosed less than four years after first exposure cannot be certified as 9/11-related.

Most basal cell carcinoma claimants meet the four-year requirement on its face. If the first date of 9/11 exposure occurred in September 2001 or in the weeks and months following, basal cell carcinomas diagnosed from September 2005 forward satisfy latency. Diagnoses from 2010, 2015, or 2020 are all well past the latency threshold.

The two-year VCF registration deadline runs from the date the WTC Health Program certifies the basal cell carcinoma as 9/11-related, not from the date of diagnosis. Registration preserves the right to file a claim; the actual claim filing deadline is October 1, 2090 for all claimants. A basal cell carcinoma diagnosed years ago remains eligible for certification.

What is the VCF payout for 9/11 basal cell carcinoma?

Certified 9/11 basal cell carcinoma qualifies claimants for free medical treatment through the WTC Health Program, and allows the claimant to submit a claim for financial compensation through the September 11th Victim Compensation Fund. The VCF's non-economic loss award for basal cell carcinoma is published in its Non-Economic Loss Awards and Certified Conditions Fact Sheet.

Baseline non-economic loss award for basal cell carcinoma

• Basal cell carcinoma baseline: $90,000. Basal cell carcinoma is compensated at the non-melanoma skin cancer baseline of $90,000 under VCF Policies & Procedures Section 2.1. This is the lower end of the VCF cancer range and reflects BCC's generally favorable prognosis and typically localized treatment. The $90,000 figure applies to a certified BCC diagnosis on its own record.
• Multiple basal cell carcinomas. Many claimants develop more than one basal cell carcinoma over the years. The VCF's non-economic loss framework is condition-based rather than lesion-based, so multiple BCCs on the same record are typically compensated within the non-melanoma skin cancer framework of $90,000 rather than as separate awards. Full documentation of the history matters for the medical record and for economic loss.
• Basal cell carcinoma with a certified [squamous cell carcinoma](/cancers/squamous-cell-carcinoma). Where a claimant has both a certified basal cell carcinoma and a certified squamous cell carcinoma, both fall within the non-melanoma skin cancer framework of $90,000. Compensation is not doubled by adding a second non-melanoma skin cancer diagnosis, but a full history of certified skin cancer supports the aggregate framework where other certified conditions are also present.

Aggregate compensation with melanoma or other certified conditions

• Basal cell carcinoma plus a certified [melanoma](/cancers/melanoma): $300,000 combined. Where a claimant has both a certified basal cell carcinoma and a certified melanoma on the same record, the combined non-economic loss award is $300,000 across the two skin cancers. This is not $90,000 plus $250,000 — the VCF weighs severity across certified conditions rather than simply adding baseline amounts.
• Aggregate up to $340,000. Where a claimant has additional certified conditions beyond skin cancer, aggregate non-economic loss compensation may reach the current VCF maximum of $340,000. The $340,000 aggregate is reserved for claims involving multiple certified cancers or a certified cancer alongside another certified condition of extraordinary severity.

Economic loss and wrongful death compensation

In addition to non-economic loss, the VCF may award economic loss for medical expenses, lost earnings, and other financial impacts from basal cell carcinoma treatment. Economic loss can be meaningful in cases involving Mohs micrographic surgery on the face, reconstructive surgery following extensive excision, treatment of morpheaform or recurrent lesions, or multiple procedures over time.

Wrongful death compensation, while rare in basal cell carcinoma given its low mortality, is available to the personal representatives of individuals who died from a 9/11-related BCC in the unusual case of aggressive or metastatic disease. Attorney fees for VCF claims are capped at 10% by federal statute.

How Baione Law handles a 9/11 basal cell carcinoma claim

Baione Law represents 9/11 basal cell carcinoma claimants at every stage:

1. Free Case Review. The firm evaluates presence in the exposure zone, exposure category, basal cell carcinoma diagnosis and history of any additional skin cancers, and current WTCHP certification status. No cost, no obligation.
2. WTC Health Program enrollment and certification support. For claimants not yet enrolled, the firm assists with enrollment and coordinates dermatology and pathology record submission to WTCHP medical providers for certification, including for the full history of basal cell carcinoma diagnoses.
3. VCF registration and claim filing. The firm registers the claim, files the compensation claim, and prepares supporting documentation including presence, exposure, pathology, and treatment history.
4. Medical records and impact documentation. The firm compiles the medical, economic, and non-economic loss documentation the VCF requires, particularly relevant where a claimant has multiple certified skin cancers or a basal cell carcinoma alongside other certified conditions.
5. Award, appeals, and amendments. After the VCF issues the award, the firm reviews it, files an appeal if warranted, and handles amendments for subsequent certified conditions, including any certification of a squamous cell carcinoma or melanoma that changes the compensation framework.

Attorney fees are capped at 10% by federal statute.